Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
Fiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
PLoS Medicine (2021) Vol. 18, Iss. 7, pp. e1003656-e1003656
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
Daniele Focosi, Fabrizio Maggi
Reviews in Medical Virology (2021) Vol. 31, Iss. 6
Open Access | Times Cited: 161
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Matthias Becker, Alex Dulovic, Daniel Junker, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 149
Evolutionary trajectory of SARS-CoV-2 and emerging variants
Jalen Singh, Pranav Pandit, Andrew G. McArthur, et al.
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 141
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, et al.
EBioMedicine (2022) Vol. 84, pp. 104270-104270
Open Access | Times Cited: 138
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Yihao Liu, Qin Zeng, Caiguanxi Deng, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 122
SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses
Marios Koutsakos, Arnold Reynaldi, Wen Shi Lee, et al.
Immunity (2023) Vol. 56, Iss. 4, pp. 879-892.e4
Open Access | Times Cited: 78
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, et al.
EBioMedicine (2023) Vol. 90, pp. 104545-104545
Open Access | Times Cited: 44
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Candice Clarke, Maria Prendecki, Amrita Dhutia, et al.
Kidney International (2021) Vol. 99, Iss. 6, pp. 1470-1477
Open Access | Times Cited: 69
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L
Anneliese S. Ashhurst, Arthur H. Tang, Pavla Fajtová, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2956-2970
Open Access | Times Cited: 65
SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Alberto Ospina Stella, Gregory J. Walker, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 65
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses
Harikrishnan Balachandran, Chansavath Phetsouphanh, David Agapiou, et al.
Cell Reports (2022) Vol. 38, Iss. 6, pp. 110345-110345
Open Access | Times Cited: 44
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia
Anupriya Aggarwal, Alberto Ospina Stella, Gregory J. Walker, et al.
Nature Microbiology (2022) Vol. 7, Iss. 6, pp. 896-908
Open Access | Times Cited: 43
Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients
Romain Rouet, Jake Y. Henry, Matt D. Johansen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs
Lipin Loo, Matthew A. Waller, Cesar L. Moreno, et al.
PLoS Biology (2023) Vol. 21, Iss. 2, pp. e3001967-e3001967
Open Access | Times Cited: 23
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
Porntip Intapiboon, Purilap Seepathomnarong, Jomkwan Ongarj, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1375-1375
Open Access | Times Cited: 50
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity
Yandong Shen, Jane A. Freeman, Juliette Holland, et al.
British Journal of Haematology (2021) Vol. 197, Iss. 1, pp. 41-51
Open Access | Times Cited: 41
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
Pablo García-Valtanen, Christopher M. Hope, Makutiro G. Masavuli, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 6, pp. 100651-100651
Open Access | Times Cited: 35
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals
Brian Grunau, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 29
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Yandong Shen, Jane A. Freeman, Juliette Holland, et al.
Blood (2022) Vol. 140, Iss. 25, pp. 2709-2721
Open Access | Times Cited: 29
Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
Wen Shi Lee, Hyon‐Xhi Tan, Arnold Reynaldi, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 20
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2
Chunxia Chen, Jiahui Liang, Hangzhan Hu, et al.
Analytical Biochemistry (2023) Vol. 673, pp. 115199-115199
Open Access | Times Cited: 16
Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans
Stephen J. Kent, Shiyao Li, Thakshila Amarasena, et al.
ACS Nano (2024)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top